One plausible mechanism for these effects was demonstrated by a study by Seguin et al., showing that a complex containing integrin α(v)β3, KRAS and RalB mediated tumor stemness in conjunction with resistance to EGFR TKI in carcinomas of the breast, lung and pancreas [37]. The gene discussed is KRAS; the disease is carcinoma.